<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512392</url>
  </required_header>
  <id_info>
    <org_study_id>17057JS-AS</org_study_id>
    <nct_id>NCT03512392</nct_id>
  </id_info>
  <brief_title>Role of Active Deresuscitation After Resuscitation-2</brief_title>
  <acronym>RADAR-2</acronym>
  <official_title>Role of Active Deresuscitation After Resuscitation- 2: a Pilot Randomised Controlled Trial of Conservative Fluid Management Versus Usual Care in Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Belfast Health and Social Care Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RADAR-2 will be a randomised, open-label, allocation concealed, pilot trial of conservative
      fluid administration and deresuscitation compared with usual care in patients who are
      critically ill.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal approach to fluid balance in critically ill patients is uncertain. A recent
      systematic review found low quality evidence in favour of a conservative fluid or
      deresuscitative approach (active removal of accumulated fluid using diuretics and/or renal
      replacement therapy) compared with a liberal strategy or usual care. The RADAR-2 pilot
      randomised trial will compare conservative fluid and deresuscitation with usual care in
      patients who are mechanically ventilated in an intensive care unit. The main hypothesis is
      that in critically ill patients, a post-resuscitation fluid strategy comprising conservative
      fluid administration and active deresuscitation reduces net fluid balance, is safe and
      improves clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">June 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, open-label, allocation concealed, pilot trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Group assignment and early (up to 28 day) data will be locked and unavailable to investigators undertaking 6-month follow up.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Day 3 fluid balance</measure>
    <time_frame>From beginning of day 2 to the beginning of study day 3.</time_frame>
    <description>Change in fluid balance (mL) between the beginning of study day 2 and the beginning of study day 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative fluid balance</measure>
    <time_frame>Up to the beginning of days 3 and 5, and at ICU discharge (estimated median day 7)</time_frame>
    <description>Cumulative fluid balance (mL) from ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of significant protocol violations</measure>
    <time_frame>Up to study day 5</time_frame>
    <description>Incidence of significant protocol violations (total number of patients, per site, and by nature of protocol violation) up to day 5 (intervention period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of reported adverse events</measure>
    <time_frame>Up to study day 5</time_frame>
    <description>Incidence of reported adverse events up to day 5 (intervention period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SOFA scores</measure>
    <time_frame>From baseline until day 3 and day 5</time_frame>
    <description>Change in Sequential Organ Function Assessment scores from baseline, overall and individual organ sub scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 and 180 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Duration of mechanical ventilation in survivors and non-survivors (number of days or part thereof from initiation of mechanical ventilatory support until unassisted breathing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>28 days</time_frame>
    <description>Length of ICU stay (number of days or part thereof from admission to an ICU or being under the care of a critical care team or consultant until ICU discharge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Up to day 5.</time_frame>
    <description>Incidence of new acute kidney injury defined as estimated KDIGO Stage 3 (before and after correction for fluid balance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>180 days</time_frame>
    <description>Cognitive function score (assessed using the Montreal Cognitive Assessment (MoCA-blind) instrument)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>180 days</time_frame>
    <description>Health-related quality of life (HR-QoL) (assessed using absolute values of a telephone-administered EQ-5D (EuroQoL 5 Dimension Scale) questionnaire)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean regional cerebral oxygen saturation</measure>
    <time_frame>72 hours from randomisation</time_frame>
    <description>Near infra-red spectroscopic measurement of regional cerebral oxygen saturation), mean rScO2 level (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Minimum regional cerebral oxygen saturation</measure>
    <time_frame>72 hours from randomisation</time_frame>
    <description>Near infra-red spectroscopic measurement of regional cerebral oxygen saturation), Minimum rScO2 level</description>
  </other_outcome>
  <other_outcome>
    <measure>Regional cerebral hypoxia burden</measure>
    <time_frame>72 hours from randomisation</time_frame>
    <description>Near infra-red spectroscopic measurement of regional cerebral oxygen saturation), proportion of time spent with rScO2 below thresholds of 50%, 65%, and 75%, measured as percentage of time for which rScO2 is measured.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Critical Illness</condition>
  <condition>Sepsis</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Conservative fluid and deresuscitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)
Daily assessment of eligibility for deresuscitation for 4 days (eligible if oedema in more than 1 site and cumulative fluid balance &gt; 2 litres)
Deresuscitation to target negative daily fluid balance of 1 to 3 litres:
5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care at the discretion of the treating team</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conservative fluid and deresuscitation strategy</intervention_name>
    <description>Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients</description>
    <arm_group_label>Conservative fluid and deresuscitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care strategy</intervention_name>
    <description>Usual care at the discretion of the clinical team</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Invasive mechanical ventilation

          2. Treating ICU doctor expects patient to require treatment in an ICU beyond the next
             calendar day

        Exclusion Criteria:

          1. Age &lt; 16 years

          2. Body weight &lt;40kg (measured or estimated)

          3. Diabetic ketoacidosis or Hyperosmolar hyperglycaemic state

          4. Non-traumatic subarachnoid haemorrhage

          5. Acute cardiac failure or cardiogenic shock

          6. End-stage renal failure (on dialysis)

          7. Known to be pregnant

          8. Suspected or proven active diabetes insipidus (DDAVP within 24 hours)

          9. Expected to die within 24 hours

         10. Active 'Do not attempt resuscitation' order

         11. Refusal of consent

         12. Inability of personal consultee to understand written or verbal information and for
             whom no interpreter is available

         13. Known allergy to one or more of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Silversides, MB BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belfast Health and Social Care Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jon Silversides, MB BCh</last_name>
    <phone>+442895041096</phone>
    <email>jon.silversides@belfasttrust.hscni.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danny McAuley, MD</last_name>
    <email>d.f.mcauley@qub.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Silversides</last_name>
      <phone>02895041096</phone>
      <email>radar2trial@belfastrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Ferguson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Quinn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Silversides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Silversides</last_name>
      <phone>02895041096</phone>
      <email>radar2trial@belfasttrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Ferguson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Quinn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny McAuley</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Silversides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Silversides JA, Major E, Ferguson AJ, Mann EE, McAuley DF, Marshall JC, Blackwood B, Fan E. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med. 2017 Feb;43(2):155-170. doi: 10.1007/s00134-016-4573-3. Epub 2016 Oct 12. Review.</citation>
    <PMID>27734109</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluid therapy</keyword>
  <keyword>furosemide</keyword>
  <keyword>diuretics</keyword>
  <keyword>Injections, Intravenous</keyword>
  <keyword>Infusions, Intravenous</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>Indapamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

